Pfizer reports 2024 revenues 7% higher at $63.6 billion

Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion

Budget 2025: Industry expects tax incentives and thrust on affordable healthcare

Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials

Calquence combination approved in US for untreated mantle cell lymphoma

Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone

Genome India Project marks a defining moment for country's biotechnology landscape: Modi

Modi remarked that more than 20 illustrious research institutions such as IISc, IITs, CSIR and DBT-BRIC have played a major role in this research

2025 will witness India assuming critical role in Global Biotechnology revolution, says Science Minister Dr. Jitendra Singh

India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030

Dr. Sandip Shah appointed as Chairperson of NABL-QCI

AstraZeneca appoints Iskra Reic as Executive Vice President, International

Iskra has held leadership positions across Central & Eastern Europe, Eurasia, Middle East & Africa at AstraZeneca

Sanofi invests €40 million to strengthen antibody bioproduction in France

Pfizer reports Q3 2024 revenue higher by 32% at US$ 17.7 billion

Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion

AstraZeneca advances science of infectious disease protection at IDWeek 2024

Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19